IASLC World Conference on Lung Cancer

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Treatment with firmonertinib was safe and effective for patients with EGFR P-loop and αC-helix compressing-mutated non–small cell lung cancer.

Treatment with aumolertinib led to an improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

The addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival compared with placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

The addition of durvalumab to chemotherapy prior to surgery, followed by adjuvant durvalumab, did not provide a clear clinical benefit in patients with early-stage non–small cell lung cancer harboring an EGFR mutation, according to data from the phase 3 AEGEAN trial.

Zongertinib will proceed to phase 1b evaluation at doses of 120 mg and 240 mg once daily in patients with HER2–mutant non–small cell lung cancer following preliminary efficacy signals and acceptable safety in patients with advanced HER2–mutant solid tumors enrolled in the dose-escalation portion of the phase 1a/b BEAMION Lung-1 trial.

Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.